Prasad Wealth Partners LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) in the third quarter, HoldingsChannel reports. The fund acquired 2,400 shares of the medical research company’s stock, valued at approximately $1,011,000.
Several other large investors have also made changes to their positions in AMGN. Public Sector Pension Investment Board grew its holdings in shares of Amgen by 61.6% during the 3rd quarter. Public Sector Pension Investment Board now owns 142,385 shares of the medical research company’s stock worth $58,824,000 after purchasing an additional 54,267 shares during the period. Global Retirement Partners LLC increased its position in Amgen by 2.1% during the 3rd quarter. Global Retirement Partners LLC now owns 25,032 shares of the medical research company’s stock worth $10,551,000 after purchasing an additional 510 shares in the last quarter. Legacy Financial Group LLC acquired a new stake in Amgen during the 3rd quarter worth approximately $205,000. Cibc World Market Inc. raised its holdings in Amgen by 84.0% in the third quarter. Cibc World Market Inc. now owns 120,866 shares of the medical research company’s stock valued at $50,946,000 after buying an additional 55,181 shares during the period. Finally, Cullen Capital Management LLC purchased a new position in Amgen in the third quarter valued at approximately $202,000. 76.50% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on AMGN. Citigroup lifted their price target on shares of Amgen from $405.00 to $465.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Freedom Broker lowered shares of Amgen from a “buy” rating to a “hold” rating and increased their price objective for the stock from $450.00 to $470.00 in a research report on Friday, November 6th. Sanford C. Bernstein raised their target price on shares of Amgen from $345.00 to $400.00 and gave the company a “market perform” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. lifted their target price on shares of Amgen from $350.00 to $425.00 and gave the company a “neutral” rating in a report on Wednesday, November 4th. Finally, Truist Financial upped their price target on shares of Amgen from $380.00 to $398.00 and gave the stock a “hold” rating in a research report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $425.69.
Recent Amgen Headlines
Investors following AMGN have been watching these headlines:
- Positive Sentiment: Amgen’s obesity-treatment candidate is described as a potential rival in a market led by Novo Nordisk, offering a possible future growth opportunity. Novo Nordisk versus Amgen
- Neutral Sentiment: Amgen published detailed Phase 3 results for dazodalibep in Sjögren’s disease, adding clinical information for investors; the article excerpt does not specify the results’ implications. Dazodalibep Phase 3 data
- Negative Sentiment: Prolia and XGEVA face falling sales under biosimilar competition, a headwind that makes continued growth in newer medicines important. Barclays maintained an “equal weight”/Hold view despite raising its target to $430, below the stock’s quoted $457.93 level. Barclays maintains Hold rating
Amgen Stock Performance
Shares of NASDAQ:AMGN opened at $457.93 on Wednesday. The company has a market cap of $247.70 billion, a P/E ratio of 26.56, a PEG ratio of 3.22 and a beta of 0.43. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. Amgen Inc. has a one year low of $312.39 and a one year high of $483.99. The business’s 50-day simple moving average is $427.10 and its 200 day simple moving average is $382.34.
Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. The firm had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. Amgen’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.64 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.
Amgen Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is currently 58.47%.
About Amgen
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
See Also
- Five stocks we like better than Amgen
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
